MedTrace Logo

A Long-term Follow up Study for Patients Who Participated in the GOAL Trial (GOAL-Post)

NCT05211024 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1423

Last updated 2024-08-27

No results posted yet for this study

Summary

GOAL-Post is comprised of two studies that will help refine recommendations for the duration of secondary prophylaxis for children diagnosed with latent RHD, which is currently not known

Conditions

  • Rheumatic Heart Disease

Interventions

DRUG

Penicillin G Benzathine

Participants in Aim 2 are receiving 28 days interval BPG intramuscular injection as part of standard of care

Sponsors & Collaborators

  • Uganda Heart Institute

    collaborator OTHER

  • Murdoch Childrens Research Institute

    collaborator OTHER

  • Children's Hospital Medical Center, Cincinnati

    lead OTHER

Principal Investigators

  • Andrea Z Beaton, MD · Cincinnati Chidren's hospital

Eligibility

Min Age
5 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-28
Primary Completion
2024-03-30
Completion
2024-04-30

Countries

  • Uganda

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05211024 on ClinicalTrials.gov